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Abstract
Background: Despite the considerable health impact of coeliac disease (CD), reliable estimates of the impact of diagnosis
on health care use and costs are lacking.
Aims: To quantify the volume, type and costs, in a United Kingdom primary care setting, of healthcare resources used by
individuals diagnosed with CD up to ten years before and after diagnosis, and to estimate medical costs associated with CD.
Methods: A cohort of 3,646 CD cases and a parallel cohort of 32,973 matched controls, extracted from the General Practice
Research Database (GPRD) over the period 1987–2005 were used i) to evaluate the impact of diagnosis on the average
resource use and costs of cases; ii) to assess direct healthcare costs due to CD by comparing average resource use and costs
incurred by cases vs. controls.
Results: Average annual healthcare costs per patient increased by £310 (95% CI £299, £320) after diagnosis. CD cases
experienced higher healthcare costs than controls both before diagnosis (mean difference £91; 95% CI: £86, £97) and after
diagnosis (mean difference £354; 95% CI: £347, £361). These differences were driven mainly by higher test and referral costs
before diagnosis, and by increased prescription costs after diagnosis.
Conclusions: This study shows significant additional primary care costs associated with coeliac disease. It provides novel
evidence that will assist researchers evaluating interventions in this area, and will challenge policymakers, clinicians,
researchers and the public to develop strategies that maximise the health benefits of the resources associated with this
disease.
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Introduction
Coeliac disease (CD) is an inherited chronic autoimmune
disorder that can potentially affect many organ systems beyond the
gastrointestinal tract [1,2,3]. It is triggered by ingestion of gluten,
the protein fraction of wheat, rye and barley. The disease can
develop and be diagnosed at any age. The only current available
therapy is a lifelong adherence to a gluten-free diet. Prevalence
amongst adults and children approaches 1% of the population in
international studies but rates of diagnosis are increasing in many
countries [4,5,6,7,8]. Clinical presentation may assume a broad
spectrum of symptoms and this often results in delayed or under-
diagnosis. Consequently, the disease can be considered a
concealed public health problem in various countries [9,10].
Although the health impact of CD is considerable due to
increasing prevalence rates, associated non-specific morbidity and
long-term complications [10], little is still known about the
resource use and costs to the healthcare system associated with
diagnosis of CD. The focus of the existing economic literature has
mainly been on estimating the likely costs associated with possible
CD screening programmes, or examining differences between
diagnostic strategies and technologies, or considering patient-
incurred dietary costs [11,12,13,14,15,16,17,18]. To our knowl-
edge, only two published studies, both conducted in the United
States (US), have attempted before and after assessments of the
economic impact of CD diagnosis [19,20]. They both found that
an increase in the rate of CD diagnosis was associated with a
significant reduction in healthcare services utilisation and costs.
However, these US analyses are not generally applicable to the
United Kingdom (UK) due to different health systems, patterns of
healthcare utilisation and payment mechanisms between coun-
tries. Given that no previous cost analysis of CD diagnosis has
been carried out in the UK, this study aims to fill the existing gap
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in the literature by providing new and original evidence on the
economic impact of CD in a UK context.
The main objective is to quantify the volume, type and cost of
healthcare resources used by individuals diagnosed with CD up to
ten years before and after diagnosis, with particular reference to
consultations, tests, referrals and prescriptions in the primary care
setting where non-acute care is mainly managed, and to compare
these with the costs incurred by a matched control-cohort, using
the General Practice Research Database (GPRD). Unlike previous
published studies and uniquely in the area of coeliac disease
research, we also analyse in detail the distribution of prescriptions
costs across the 15 British National Formulary (BNF) categories
[21] for both the case and control cohorts. We look at data for the
period 1987 to 2005.
Methods
The UK GPRD is one of the largest computerised databases of
anonymised longitudinal medical records from primary care.
There was, therefore, no need of patients’ consent. GPRD
contains data from 1987 onwards and currently covers a
population of over 5 million patients throughout the UK. It
includes medical diagnostic codes for consultations, tests, referrals
and details of prescriptions issued. Data are routinely subject to
quality checks in order to guarantee they are ‘up-to-standard’ [22].
Study Design
We used information supplied by GPRD staff over the period
June 1987 to October 2005. Our case-cohort comprised all
patients within GPRD with a recorded diagnosis of CD. Following
the methods of a previous published study [23], our study
population was restricted to those patients with a medical
diagnosis of CD according to one of the following Read/OXMIS
medical codes (restricted definition of CD): 2690B Coeliac
Disease, J690.00 Coeliac Disease, J690z00 Coeliac Disease
NOS, J690.13 Gluten Enteropathy, 2690D Infantile Coeliac
Disease, J690100 Acquired Coeliac Disease. A control-cohort was
identified by selecting ten controls to match each patient with CD
by age, gender and general practice. Controls were alive and
registered at the practice on the date of the first prospective, up to
standard, record of CD for cases. Controls were excluded if they
had any record of gluten-free prescription or a non-specific
reference to CD, such as gluten-free diet or gluten sensitivity.
A diagnosis date, defined as the date of the first record of CD,
was attributed to each patient with CD. Controls were assigned a
‘pseudo-diagnosis’ date coinciding with that of their matched case.
To ensure maximum reliability of data we distinguished between
‘incident cases’ – those patients with a date of diagnosis of CD at
least 12 months after their up-to-standard record on GPRD began
– and ‘prevalent cases’, including all other subjects with CD.
Primary analyses made use only of incident cases.
Data
Details of demographic and diagnostic information were
extracted or constructed from the GPRD data for the CD and
the control cohorts. They included patient age, gender, smoking
status, BMI, Charlson comorbidity score, which, by accounting for
both number and severity of comorbidity, classifies patients
according to their disease burden [24,25,26], length of observation
time and the diagnosis/pseudo-diagnosis date by calendar year
group.
Information relating to resource use for each patient over the
study period was extracted from the GPRD data. It included
number of primary care consultations, tests, referrals to out-patient
hospital care [27] and prescriptions (by BNF category). Details on
the specific composition of each resource use category and the
assumptions made for their count [21,28] can be found in the
supplementary material (File S1, Text S1).
For each patient, healthcare costs stratified by subcategory of
interest (consultations, tests, referrals and prescriptions) were
computed by multiplying units of resource use by their unit costs.
These were then summed over all resource use categories to obtain
an annual cost and total cost for each patient. Details on the
specific unit cost sources [29,30,31,32] and values can be found in
the supplementary material (File S1, Table S1). Values were
expressed in 2009/10 UK pound sterling (£). When values where
available only for 2008/09, prices were adjusted using the Hospital
and Community Health Services (HCHS) pay and price inflation
index 2009/10 [33].
Statistical Analysis
We analysed the 10-year period prior to and following diagnosis
of CD for cases, and pseudo-diagnosis for the matched control-
cohort. We considered the full 20-year period even if data on
healthcare utilisation and costs for a case or control subject were
available for less than 20 years, provided that data were available
on at least some of the matched sets of cases and controls within
the study population. Consequently, resource use and costs were
calculated on a number of cases/controls that was variable each
year over the period of study. Average annual amounts of
healthcare resource use and associated costs were calculated and
then compared for the identified CD cohort in the 10 years prior
to and following diagnosis. The aim was to evaluate the impact of
diagnosis on the average resource use and costs incurred by each
patient within a primary care setting. Similar analyses were
performed for the control-cohort. Analyses were stratified by
resource use and cost categories of interest, and by age group at
diagnosis (total costs only).
The direct healthcare costs due to CD were estimated by
comparing the average annual amounts of healthcare resources
use and costs incurred by the CD cohort with the analogous
amounts incurred by the matched control-cohort before and after
diagnosis/pseudo-diagnosis (for controls) of CD. These analyses
were also stratified by resource use and cost category of interest,
and by age group at diagnosis/pseudo-diagnosis (total costs only).
Similar analyses were conducted for costs of prescriptions by BNF
category.
We also investigated whether the widespread introduction of
serological testing, approximately between 1993 and 2000
[5,34,35,36,37,38,39] altered the patterns of healthcare utilisation
and associated costs in the CD versus non-CD cohorts. A before
and after diagnosis comparison of costs for the case and the control
cohorts was conducted by stratifying the sample by date of
diagnosis/pseudo-diagnosis for each of the cost category of
interest.
Consultations, referrals, tests and prescriptions were treated as
continuous variables and reported as number of events per patient
per year. Resource use rates and mean costs before and after
diagnosis were reported together with their standard errors. Rates
and mean differences in observed resource use and costs between
the two time periods were reported alongside 95% confidence
intervals (CI). Statistical differences in mean estimates were
evaluated using Student’s two-sided t-test [40]. Unpaired t-tests
were used to conform to the decision not to restrict analyses to
matched sets for which the ratio ‘cases to controls’ was consistently
1:10 over the time of the study. All statistical analyses were
performed using STATA version 11. Statistical significance was set
at P-values less than 0.05.
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Results
Study Population
Figure 1 shows the cases selection profile. A cohort of 11,979
cases was initially identified as patients with a medical diagnosis of
coeliac disease or dermatitis herpetiformis or a non-specific
reference to coeliac disease or a prescription for gluten free
products between 1st June 1987 and 31st October 2005 (wider
definition of CD). Of these, 561 patients were excluded because of
ascertained inconsistencies between the diagnosis date and the
patient’s date of registration with the practice. No data on the
variable ‘practice-up-to-standard’ were available for further 109
patients, who were excluded. Our decision to focus only on
incident cases led to the exclusion of a further 5,420 prevalent
cases, reducing the sample to 5,889 patients. A further 2,243 cases
were removed because they did not satisfy the more restricted
definition of CD. Results are, therefore, based on 3,646 incident
cases and the corresponding controls matched on a 1:10 ratio. A
further refinement of the control-cohort was the exclusion of 3,487
individuals as ‘no consulters’ on the grounds that they did not
consult over the 12 months before and after the pseudo-diagnosis
date.
Table 1 displays demographic and diagnostic information for
patients in our study. The 3,646 cases and the 32,973 matched
controls contributed 37,208 and 352,205 observed patient years,
respectively. The mean observed time was 10.21 years for cases
and 10.68 years for controls, with mean pre-diagnosis/pseudo-
diagnosis time of 5.01 and 5.41 years for the case and the control
cohorts, respectively. The corresponding mean observed time after
diagnosis was 5.20 years for cases, and 5.28 years for controls.
The mean age at diagnosis of the incident cases was 43.76 years,
and 66% of them were women. The percentage of current smokers
was higher in the control-cohort than in the CD cohort (19%
versus 15%). About 50% of cases were underweight/normal,
compared with only 34% among controls. 60% of cases had no
comorbid disease, compared with 65% of controls. The difference
remained distinct also for low values of the Charlson comorbidity
index (25% of cases versus 21% of controls had an index score of
1). Finally, about 61% of cases were diagnosed in 2000 or later.
That period followed the widespread adoption of highly sensitive
and specific diagnostic serological tests to detect the disease.
Impact of Diagnosis of Coeliac Disease on Healthcare
Resource Use and Costs
The coeliac cohort had a lower rate of consultations (5.8 vs 6.9),
tests (1.9 vs 3) and prescriptions (14.3 vs 40.7) in the 10 year prior
to diagnosis than following diagnosis (Table 2). Rate differences
were statistically significant. Only the referral rate showed a small
but statistically significant decrease between the two periods (0.3 vs
0.21). The rates of resource use for the control-cohort (Table 2)
were lower than for case-cohort but, with the exception of
referrals, they slightly increased after pseudo-diagnosis. Although
statistically significant, the magnitude of these rate differences was
almost negligible and more likely driven by secular time trends in
healthcare utilisation.
Total annual healthcare costs increased by £310 (£340 vs
£650, 95% CI: £299, £320) in the case-cohort, following CD
diagnosis. This 91% increase was mainly driven by the trebling of
prescription costs (£ 137 vs £ 432, 95% CI: £ 287, £302). The
modest, but statistically significant increase in consultation costs (£
20, 95% CI: £16.4, £24.5) and test costs (£ 4.1, 95% CI: £3.6,
£4.6) was partially offset by the reduction in referral costs
(2£12.1, 95% CI:2£13.9,2£10.26). Stratification of total
annual healthcare costs by age group at diagnosis (File S1, Table
S2) show that total costs per patient more than doubled after
diagnosis for the age group ‘46 or more’, whilst it increased by
81% and 84% for age groups ‘0–189 and ‘19–459, respectively.
Figure 2 shows that in the coeliac cohort, the average cost per
patient increased gradually until three years before diagnosis (from
£231 to £296). Costs continued to increase at a faster rate until a
year after diagnosis (up to £768), undergoing a rapid decrease the
year after, until they stabilised at around £600 from the sixth year
after diagnosis onwards. The average cost per patient for the
control-cohort underwent a more modest and gradual increase
over the whole 20-year period, from £198 to £310.
Table 3 shows that, for the majority of BNF categories, the cost
of prescriptions for cases was larger than the corresponding costs
for controls. The BNF categories more obviously thought to be
associated with CD were ‘gastro-intestinal system’ (BNF 1) and
‘food and nutrition’ (BNF 9). Although small in magnitude, the
average cost for prescriptions in BNF 1 increased by 38% for the
case-cohort (£10.7 vs £ 14.8, 95% CI: £ 3.3, £ 4.8) before and
after diagnosis. The control-cohort underwent a corresponding
increase of 35%. More strikingly, the average costs for ‘food and
nutrition’ (BNF 9) prescriptions (including gluten-free products
such as gluten-free bread, pasta, flour, biscuits etc.) for the case-
cohort became 25 times larger than in the pre-diagnosis period
(£10 vs £246, 95% CI: £ 231, £240) and never returned to the
pre-diagnosis levels. The corresponding increase for the controls
was 58%. A more detailed analysis focusing exclusively on gluten-
free and special diet food supplements revealed that the latter were
responsible for 89% of the increased prescriptions costs in BNF 9
after diagnosis (£1.8 vs £220, 95% CI: £214, £222). With respect
to the costs for the other BNF categories, our results were
consistent with clinical and epidemiological evidence on health
problems associated with CD [2,3,10]: for instance, the apparently
higher prescribing for osteoporosis (BNF 6). The associated
prescription costs for the case-cohort increased by 59% for BNF
6, while they increased by 42% for the control-cohort. Growing
prescription costs for cases were observed also for BNF categories
3 (respiratory system), 4 (central nervous systems), 11 (eye) [2,3,10]
and ‘Miscellaneous’ (which included some gluten-free products).
Table 4 displays the total and disaggregated healthcare costs for
the case and control cohorts stratified by date of diagnosis/pseudo-
diagnosis. Figure 3 shows that the pre-2000 cohorts of both cases
and controls had lower costs than the corresponding post-1999
cohorts over almost the whole sample period.
Cost Associated with Coeliac Disease
Over the 10-year period preceding diagnosis, the CD cohort
experienced significantly higher total costs of £91 compared with
the control-cohort (mean total costs: £340 vs £249, 95% CI: £86,
£97) (Table 2). This difference was mainly driven by higher costs
for tests and referrals (70% and 50%, respectively, compared with
matched controls), while consultations and prescriptions costs
contributed to a lesser extent (less than 40% higher than for
controls). After diagnosis, the difference expanded to £354 (£650
vs £296, 95% CI: £347, £361). This was the results of a trebling
of prescriptions costs for cases, an increase in consultations costs
(42% higher than for controls) and a decrease in tests and referrals
costs (still, however, 49% and 13%, respectively, higher than for
controls). All differences reached statistical significance. Analyses
stratified by age group (File S1, Table S2) show that over the 10-
year period preceding diagnosis the case-control difference in
annual total cost per patient was homogeneous across age groups
‘19–45’ and ‘46 or more’, but 13% higher for the age group ‘0-18’
(£241 vs £139, 95% CI: £93, £111). After diagnosis, the costs
difference between cases and controls were similar for age groups
Cost of Coeliac Disease before and after Diagnosis
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41308
‘0–18’ and ‘19–45’, but resulted 29% higher for age group ‘46 or
more’ (£810 vs £409, 95% CI: £390, £413).
A closer look at the prescription costs (Table 3) reveals that the
case-cohort made a significantly higher use of drugs in BNF
categories 1 (gastrointestinal), 6 (endocrinology) and 9 (nutrition
and blood) both before and after diagnosis. The pre-diagnosis
prescription costs for the cohort of cases for BNF 1 and 6 were
almost double compared with the costs incurred by the control-
cohort; costs for BNF 9 were quadruple, and when focusing only
on the subset of prescriptions for food supplements (gluten-free
and special diet products) costs became 15 times higher. After
diagnosis, the proportion of costs of cases to controls remained
almost unchanged for BNF 1 and 6 but was 65 times higher for
cases than for controls for BNF category 9. For the other BNF
categories for which cost differences between case and control
cohorts were statistically significant, the higher costs for cases
compared with controls ranged from 9% (BNF 3; respiratory) to
41% (BNF 13: skin) before diagnosis, and from 16% (BNF 4:
nervous system) to 59% (BNF 12: ear, nose & oropharynx), after
diagnosis.
Table 4 stratifies healthcare costs by diagnosis date. Compar-
isons of the stratified analyses with those run on the whole sample
period (Table 2) indicate that cost differences between cases and
controls were larger before diagnosis and smaller after diagnosis in
the period up to 1999, whilst in the post-1999 period that situation
was reversed.
Discussion
To the best of our knowledge, this is the first detailed evaluation
of the resource use and costs before and after diagnosis of CD in
the primary care setting of the UK healthcare system.
Average per-patient annual healthcare costs in primary care
significantly increased by 91% for CD patients after they had been
Figure 1. Cases selection profile.
doi:10.1371/journal.pone.0041308.g001
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diagnosed with the disease. The trend of increased expenditure
was stronger in the immediate pre- and post-diagnosis period,
which is consistent with clinical practice (Figure 2). Diagnosis
usually follows a period of more intense utilisation of healthcare, of
which it is the outcome, and it is also followed by an equivalent, if
not larger, use of healthcare resources [8] after diagnosis, as
Table 1. Details on observation time and personal characteristics of coeliac disease cohort and control cohort1.
Variables Coeliac Disease cohort (n=3,646) Control cohort (n =32,973)
Mean (median) observed time Overall 10.21 (9.97)1 10.68 (10.52)
Before diagnosis 5.01 (4.21) 5.41 (4.67)
After diagnosis 5.20 (4.00) 5.28 (4.12)
Total observed time (years)2 37,208 352,205
Gender Female 2,389 (65.52) 22,220 (67.39)
Male 1,257 (34.48) 10,753 (32.61)
Mean age at beginning of
observed time (years)
38.85 38.72
Age group at beginning of
observed time (categories)
0–3 367 (10.07) 3,507 (10.64)
.3–15 237 (6.50) 2,080 (6.31)
.15–25 287 (7.87) 2,729 (8.28)
.25–35 644 (17.66) 5,659 (17.16)
.35–45 649 (17.80) 5,715 (17.33)
.45–55 615 (16.87) 5,467 (16.61)
.55–65 452 (12.40) 4,144 (12.57)
.65–75 287 (7.87) 2,709 (8.22)
.75 108 (2.96) 954 (2.89)
Age at diagnosis or pseudo-
diagnosis (controls) date
Mean 43.76 44
0–18 576 (15.80) 5,210 (15.80)
19–45 1,248 (34.23) 11,054 (33.52)
46 or more 1,822 (49.97) 16,709 (50.67)
Smoking status3 Non-smoker 1,937 (53.12) 15,459 (46.88)
Former smoker 537 (14.73) 4,838 (14.67)
Smoker 552 (15.14) 6,297 (19.10)
Unknown 620 (17.00) 6,379 (19.35)
BMI3 Underweight/normal 1,835 (50.33) 11,302 (34.28)
Overweight/obese 874 (23.97) 12,111 (36.73)
Unknown 937 (25.70) 9,560 (28.99)
Charlson comorbidity score 0 2,188 (60.01) 21,516 (65.25)
1 919 (25.21) 7,105 (21.55)
2 287 (7.87) 2,238 (6.79)
3 or more 249 (6.93) 2,080 (6.31)
Unknown 3 (0.08) 34 (0.10)
Diagnosis/pseudo-diagnosis year 1987–1990 19 (0.52) 165 (0.50)
1991–1993 308 (8.45) 2,719 (8.25)
1994–1996 407 (11.16) 3,535 (10.72)
1997–1999 695 (19.06) 6,248 (18.95)
2000–2003 1,456 (39.93) 13,235 (40.14)
2004–2005 761 (20.87) 7,071 (21.44)
Diagnosis/pseudo-diagnosis
up to 1999 and after
1987–1999 1,429 (39.19) 12,667 (38.42)
2000–2005 2,217 (60.81) 20,306 (61.58)
1Values are numbers and percentages are presented in parentheses.
2Matching was performed between cases and controls not on individual years.
3most recent.
doi:10.1371/journal.pone.0041308.t001
Cost of Coeliac Disease before and after Diagnosis
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41308
T
a
b
le
2
.
R
e
so
u
rc
e
u
se
an
d
co
st
s:
av
e
ra
g
e
an
n
u
al
am
o
u
n
ts
o
f
h
e
al
th
ca
re
re
so
u
rc
e
u
se
an
d
co
st
s
p
e
r
p
at
ie
n
t
in
C
D
ve
rs
u
s
n
o
n
-C
D
co
h
o
rt
s
(f
o
r
a
m
ax
im
u
m
o
f
1
0
ye
ar
s
b
e
fo
re
an
d
af
te
r
d
ia
g
n
o
si
s)
.
C
a
se
s
C
o
n
tr
o
ls
C
a
se
-C
o
n
tr
o
l
D
if
fe
re
n
ce
C
a
se
s
a
s
a
p
ro
p
o
rt
io
n
o
f
co
n
tr
o
ls
B
e
fo
re
1
(B
)
A
ft
e
r1
(A
)
A
-B
2
B
e
fo
re
1
(B
)
A
ft
e
r1
(A
)
A
–
B
2
B
e
fo
re
2
A
ft
e
r2
B
e
fo
re
2
A
ft
e
r2
R
ES
O
U
R
C
E
U
S
E
C
o
n
su
lt
a
ti
o
n
s
5
.8
(0
.0
4
8
)
6
.9
(0
.0
6
0
)
1
.1
(1
.0
0
6
,
1
.3
)
4
.3
(0
.0
1
2
)
4
.9
(0
.0
1
5
)
0
.6
5
(0
.6
1
,
0
.6
9
)
1
.5
(1
.4
,
1
.6
)
2
.0
1
(1
.9
,
2
.1
)
1
.3
5
(1
.3
2
,
1
.3
7
)
1
.4
1
(1
.3
9
,
1
.4
4
)
T
e
st
s
1
.9
(0
.0
3
1
)
3
(0
.0
4
7
)
1
.1
(0
.9
,
1
.2
)
1
.1
(0
.0
0
7
)
2
.0
1
(0
.0
1
1
)
0
.9
(0
.8
8
,
0
.9
3
)
0
.8
(0
.7
8
,
0
.8
8
)
0
.9
8
(0
.9
0
,
1
.0
5
)
1
.7
3
(1
.7
0
,
1
.8
1
)
1
.4
9
(1
.4
4
,
1
.5
4
)
O
u
tp
a
ti
e
n
t
re
fe
rr
a
ls
0
.3
(0
.0
0
5
)
0
.2
1
(0
.0
0
5
)
2
0
.9
(2
0
.1
1
,
2
0
.0
8
)
0
.2
1
(0
.0
0
2
)
0
.1
9
(0
.0
0
2
)
2
0
.0
2
(2
0
.0
2
3
,-
0
.0
1
4
)
0
.0
9
(0
.0
8
9
,
0
.1
0
8
)
0
.0
2
(0
.0
1
3
,
0
.0
3
2
)
1
.4
3
(1
.3
8
,
1
.4
8
)
1
.1
1
(1
.0
5
,
1
.1
6
)
P
re
sc
ri
p
ti
o
n
s
1
4
.3
(0
.1
7
9
)
4
0
.7
(0
.3
4
1
)
2
6
.4
(2
5
.6
,
2
7
.1
)
1
1
.2
(0
.0
5
1
)
1
5
(0
.0
7
6
)
3
.8
(3
.7
,
4
.0
1
)
3
.1
(2
.8
,
3
.4
)
2
5
.6
(2
5
.1
,
2
6
.1
)
1
.2
5
(1
.2
4
,
1
.3
1
)
2
.7
1
(2
.6
6
,
2
.7
6
)
C
O
S
T
S
C
o
n
su
lt
a
ti
o
n
s
co
st
s
£
1
6
4
(1
.3
6
3
)
£
1
8
4
(1
.5
7
0
)
£
2
0
(£
1
6
.4
,
£
2
4
.5
)
£
1
2
0
(0
.3
4
6
)
£
1
3
0
(0
.3
9
8
)
£
1
0
(£
8
.8
,
£
1
0
.9
)
£
4
3
.6
(£
4
1
.3
,
£
4
5
.8
)
£
5
4
.2
(£
5
1
.6
,
£
5
6
.7
)
1
.3
7
(1
.3
4
,
1
.3
9
)
1
.4
2
(1
.3
9
,
1
.4
4
)
T
e
st
s
co
st
s
£
9
(0
.1
3
6
)
£
1
3
.1
(0
.2
0
5
)
£
4
.1
(£
3
.6
,
£
4
.6
)
£
5
.3
(0
.0
3
2
)
£
8
.8
(0
.0
4
8
)
£
3
.5
(£
3
.4
,
£
3
.6
)
£
3
.7
(£
3
.5
,
£
4
)
£
4
.3
(£
4
.0
1
,
£
4
.6
)
1
.7
0
(1
.6
5
,
1
.7
6
)
1
.4
9
(1
.4
4
,
1
.5
4
)
O
u
tp
a
ti
e
n
t
re
fe
rr
a
ls
co
st
s
£
3
9
.2
(0
.6
7
7
)
£
2
7
.1
(0
.6
2
4
)
2
£
1
2
.1
(2
£
1
3
.9
,
2
£
1
0
.2
6
)
£
2
6
.1
(0
.1
8
9
)
£
2
3
.9
(0
.2
0
5
)
2
£
2
.2
(2
£
2
.7
5
,
2
£
1
.6
5
)
£
1
3
.1
(£
1
2
,
£
1
4
.3
1
)
£
3
.2
(£
2
.0
8
,
£
4
.4
5
)
1
.5
0
(1
.4
5
,
1
.5
6
)
1
.1
3
(1
.0
8
,
1
.1
9
)
P
re
sc
ri
p
ti
o
n
s
co
st
s
£
1
3
7
(1
.7
4
3
)
£
4
3
2
(3
.6
1
4
)
£
2
9
5
(£
2
8
7
,
£
3
0
2
)
£
1
0
6
(0
.5
1
3
)
£
1
4
2
(0
.7
5
3
)
£
3
6
(£
3
4
.3
,
£
3
7
.8
)
£
3
0
.7
(£
2
7
.4
,
£
3
4
.0
3
)
£
2
8
9
(£
2
8
4
,
£
2
9
4
)
1
.2
9
(1
.2
6
,
1
.3
3
)
3
.0
4
(2
.9
8
,
3
.1
0
)
T
o
ta
l
co
st
s
£
3
4
0
(2
.9
6
)
£
6
5
0
(4
.6
8
)
£
3
1
0
(£
2
9
9
,
£
3
2
0
)
£
2
4
9
(0
.7
9
)
£
2
9
6
(1
.0
7
)
£
4
7
(£
4
5
,
£
5
0
)
£
9
1
(£
8
6
,
£
9
7
)
£
3
5
4
(£
3
4
7
,
£
3
6
1
)
1
.3
7
(1
.3
4
,
1
.3
9
)
2
.2
0
(2
.1
6
,
2
.2
3
)
1
St
an
d
ar
d
e
rr
o
r
in
p
ar
e
n
th
e
se
s.
2
C
o
n
fi
d
e
n
ce
in
te
rv
al
in
p
ar
e
n
th
e
se
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
4
1
3
0
8
.t
0
0
2
Cost of Coeliac Disease before and after Diagnosis
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41308
T
a
b
le
3
.
A
ve
ra
g
e
an
n
u
al
co
st
fo
r
p
re
sc
ri
p
ti
o
n
s
p
e
r
p
at
ie
n
t
b
y
B
ri
ti
sh
N
at
io
n
al
Fo
rm
u
la
ry
(B
N
F)
ca
te
g
o
ry
in
C
D
ve
rs
u
s
n
o
n
-C
D
co
h
o
rt
s
(f
o
r
a
m
ax
im
u
m
o
f
1
0
ye
ar
s
b
e
fo
re
an
d
af
te
r
d
ia
g
n
o
si
s)
.
C
a
se
s
C
o
n
tr
o
ls
C
a
se
-C
o
n
tr
o
l
D
if
fe
re
n
ce
C
a
se
s
a
s
a
p
ro
p
o
rt
io
n
o
f
co
n
tr
o
ls
B
e
fo
re
1
(B
)
A
ft
e
r1
(A
)
A
–
B
2
B
e
fo
re
1
(B
)
A
ft
e
r1
(A
)
A
–
B
2
B
e
fo
re
2
A
ft
e
r2
B
e
fo
re
2
A
ft
e
r2
B
N
F
ca
te
g
o
ry
B
N
F
0
1
:
G
a
st
ro
in
te
st
in
a
l
£
1
0
.7
(0
.2
4
1
)
£
1
4
.8
(0
.3
0
3
)
£
4
.1
(£
3
.3
,
£
4
.8
)
£
5
.9
(0
.0
5
6
)
£
8
(0
.0
7
8
)
£
2
.1
(£
1
.8
,
£
2
.2
)
£
4
.8
(£
4
.4
,
£
5
.2
)
£
6
.8
(£
6
.3
,
£
7
.3
)
1
.8
1
(1
.7
1
,
1
.9
1
)
1
.8
5
(1
.7
7
,
1
.9
3
)
B
N
F
0
2
:
C
a
rd
io
v
a
sc
u
la
r
£
1
1
.6
(0
.3
4
3
)
£
1
8
(0
.4
6
9
)
£
6
.4
(£
5
.3
,
£
7
.5
)
£
1
4
.1
(0
.1
1
5
)
£
2
3
(0
.1
7
6
)
£
8
.9
(£
8
.5
,
£
9
.3
)
2
£
2
.5
(2
£
3
.2
,
2
£
1
.7
)
2
£
5
(2
£
6
,
2
£
3
.9
)
0
.8
2
(0
.7
8
,
0
.8
7
)
0
.7
8
(0
.7
4
,
0
.8
3
)
B
N
F
0
3
:
R
e
sp
ir
a
to
ry
£
1
8
.1
(0
.5
8
3
)
£
2
6
(0
.8
2
6
)
£
7
.9
(£
5
.9
,
£
9
.8
)
£
1
6
.6
(0
.1
8
2
)
£
2
0
(0
.2
1
8
)
£
3
.4
(£
2
.8
,
£
3
.9
)
£
1
.5
(£
0
.3
,
£
2
.7
)
£
6
(£
4
.6
,
7
.4
)
1
.0
9
(1
.0
2
,
1
.1
6
)
1
.3
0
(1
.2
1
,
1
.3
8
)
B
N
F
0
4
:
N
e
rv
o
u
s
sy
st
e
m
£
3
1
(0
.6
7
8
)
£
4
1
.4
(1
.0
1
5
)
£
1
0
.4
(£
8
,
£
1
2
.8
)
£
2
5
.5
(0
.2
0
2
)
£
3
5
.8
(0
.3
0
3
)
£
1
0
.3
(£
9
.6
,
£
1
1
)
£
5
.5
(£
4
.2
,
£
6
.8
)
£
5
.6
(£
3
.7
,
£
7
.5
)
1
.2
2
(1
.1
6
,
1
.2
7
)
1
.1
6
(1
.1
0
,
1
.2
2
)
B
N
F
0
5
:
In
fe
ct
io
n
s
£
3
.7
(0
.0
5
4
)
£
4
.1
(0
.0
7
0
)
£
0
.4
(£
0
.3
,
£
0
.6
)
£
3
(0
.0
1
6
)
£
3
.1
(0
.0
1
9
)
£
0
.1
(£
0
.0
4
,
£
0
.1
3
)
£
0
.7
(£
0
.6
,
£
0
.8
)
£
1
(£
0
.9
5
,
£
1
.1
9
)
1
.2
3
(1
.2
0
,
1
.2
7
)
1
.3
2
(1
.2
9
,
1
.3
8
)
B
N
F
0
6
:
E
n
d
o
cr
in
o
lo
g
y
£
1
9
.2
(0
.4
4
4
)
£
3
0
.5
(0
.6
0
2
)
£
1
1
.3
(£
9
.9
,
£
1
2
.8
)
£
1
1
.8
(0
.1
0
8
)
£
1
6
.7
(0
.1
5
6
)
£
4
.9
(£
4
.6
,
£
5
.3
)
£
7
.4
(£
6
.7
,
£
8
.1
)
£
1
3
.8
(£
1
2
.8
,
£
1
4
.8
)
1
.6
3
(1
.5
4
,
1
.7
0
)
1
.8
3
(1
.7
5
,
1
.9
0
)
B
N
F
0
7
:
O
b
st
e
tr
ic
s
&
G
y
n
a
e
co
lo
g
y
£
5
.4
(0
.1
4
0
)
£
5
.7
(0
.1
8
2
)
£
0
.3
(2
£
0
.1
,
£
0
.8
)
£
5
.3
(0
.0
4
6
)
£
5
.5
(0
.0
5
9
)
£
0
.2
(£
0
.0
1
,
£
0
.3
)
£
0
.1
(2
£
0
.2
6
,
£
0
.3
3
)
£
0
.2
(2
£
0
.1
5
,
£
0
.6
)
1
.0
2
(0
.9
6
,
1
.0
7
)
1
.0
4
(0
.9
7
,
1
.1
1
)
B
N
F
0
8
:
M
a
li
g
n
a
n
t
d
is
e
a
se
£
3
.6
(0
.3
2
7
)
£
7
.5
(0
.6
2
2
)
£
3
.9
(£
2
.6
,
£
5
.3
)
£
4
(0
.1
3
4
)
£
6
.3
(0
.1
8
6
)
£
2
.3
(£
1
.8
,
£
2
.7
)
2
£
0
.4
(2
£
1
.3
,
£
0
.4
2
)
£
1
.2
(£
0
.0
9
,
£
2
.4
)
0
.9
0
(0
.7
3
,
1
.0
8
)
1
.1
9
(0
.9
9
,
1
.4
1
)
B
N
F
0
9
:
N
u
tr
it
io
n
&
b
lo
o
d
£
1
0
(0
.2
5
3
)
£
2
4
6
(2
.2
7
6
)
£
2
3
6
(£
2
3
1
,
£
2
4
0
)
£
2
.4
(0
.0
4
4
)
£
3
.8
(0
.0
7
1
)
£
1
.4
(£
1
.2
,
£
1
.5
)
£
7
.6
(£
7
.3
,
£
7
.9
)
£
2
4
2
(£
2
4
0
,
£
2
4
3
)
4
.1
7
(3
.9
1
,
4
.4
2
)
6
4
.7
(6
2
.1
,
6
7
.3
)
B
N
F
0
9
:
S
u
b
se
t
o
f
fo
o
d
su
p
p
le
m
e
n
ts
3
£
1
.8
(0
.0
8
3
)
£
2
2
0
(2
.1
6
)
£
2
1
8
(£
2
1
4
,
£
2
2
2
)
£
0
.1
2
(0
.0
1
2
)
£
0
.2
3
(0
.0
2
1
)
£
0
.1
1
(£
0
.0
7
,
£
0
.1
6
)
£
1
.7
(£
1
.6
3
,
£
1
.8
1
)
£
2
1
9
(£
2
1
8
,
£
2
2
1
)
1
5
(1
2
.2
4
,
1
8
.9
5
)
9
5
7
(8
1
0
,
1
1
6
6
)
B
N
F
1
0
:
M
u
sc
u
lo
sk
e
le
ta
l
&
jo
in
t
d
is
e
a
se
£
6
(0
.1
4
3
)
£
5
.8
(0
.1
4
9
)
2
£
0
.2
(2
£
0
.6
,
£
0
.1
9
)
£
5
(0
.0
4
1
)
£
5
.8
4
(0
.0
5
3
)
£
0
.8
(£
0
.7
5
,
£
1
)
£
1
(£
0
.7
,
£
1
.3
)
2
£
0
.0
4
(2
£
0
.4
2
,
£
0
.2
4
)
1
.2
0
(1
.1
4
,
1
.2
5
)
0
.9
9
(0
.9
3
,
1
.0
4
)
B
N
F
1
1
:
E
y
e
£
2
.3
(0
.0
9
8
)
£
4
.2
(0
.1
9
7
)
£
1
.9
(£
1
.5
,
£
2
.3
)
£
2
.2
(0
.0
3
6
)
£
3
(0
.0
4
9
)
£
0
.8
(£
0
.6
2
,
£
0
.8
6
)
£
0
.1
(2
£
0
.1
8
,
£
0
.2
9
)
£
1
.2
(£
0
.9
1
,
£
1
.5
4
)
1
.0
5
(0
.9
4
,
1
.1
3
)
1
.4
0
(1
.2
6
,
1
.5
3
)
B
N
F
1
2
:
E
a
r,
n
o
se
&
o
ro
p
h
a
ry
n
x
£
2
(0
.0
5
9
)
£
2
.7
(0
.0
8
1
)
£
0
.7
(£
0
.5
,
£
0
.9
)
£
1
.4
(0
.0
1
6
)
£
1
.7
(0
.0
2
1
)
£
0
.3
(£
0
.2
6
,
£
0
.3
6
)
£
0
.6
(£
0
.4
5
,
£
0
.6
6
)
£
1
(£
0
.8
4
,
£
1
.1
1
)
1
.4
3
(1
.3
1
,
1
.4
8
)
1
.5
9
(1
.4
8
,
1
.6
8
)
B
N
F
1
3
:
S
k
in
£
5
.8
(0
.1
5
8
)
£
7
.3
(0
.1
8
5
)
£
1
.5
(£
1
,
£
1
.9
)
£
4
.1
(0
.0
3
6
)
£
4
.7
(0
.0
4
5
)
£
0
.6
(£
0
.5
1
,
£
0
.7
3
)
£
1
.7
(£
1
.5
,
£
2
)
£
2
.6
(£
2
.3
,
£
2
.9
)
1
.4
1
(1
.3
4
,
1
.5
0
)
1
.5
5
(1
.4
6
,
1
.6
3
)
B
N
F
1
4
:
Im
m
u
n
o
lo
g
ic
a
l
p
ro
d
u
ct
s
£
1
.6
(0
.0
3
9
)
£
1
.7
(0
.0
5
0
)
£
0
.1
(2
£
0
.0
3
,
£
0
.2
)
£
1
.4
6
(0
.0
1
2
)
£
1
.3
9
(0
.0
1
2
)
2
£
0
.0
7
(2
£
0
.1
,
2
£
0
.0
3
)
£
0
.1
(£
0
.0
2
,
£
0
.1
7
)
£
0
.3
(£
0
.1
8
,
£
0
.3
4
)
1
.1
0
(1
.0
1
,
1
.1
2
)
1
.2
2
(1
.1
1
,
1
.2
6
)
B
N
F
1
5
:
A
n
a
e
st
h
e
si
a
£
0
.3
(0
.0
4
1
)
£
0
.5
(0
.0
6
9
)
£
0
.2
(2
£
0
.0
1
,
£
0
.3
)
£
0
.3
4
(0
.0
1
3
)
£
0
.4
(0
.0
1
8
)
£
0
.0
6
(£
0
.0
3
,
£
0
.1
2
)
2
£
0
.0
4
(2
£
0
.1
,
£
0
.0
6
)
£
0
.1
(2
£
0
.0
7
,
£
0
.1
7
)
0
.8
8
(0
.7
3
,
1
.2
2
)
1
.2
5
(0
.8
3
,
1
.5
4
)
M
is
ce
ll
a
n
e
o
u
s
£
5
.8
(0
.2
3
9
)
£
1
6
.1
(0
.5
3
0
)
£
1
0
.3
(£
9
.2
,
£
1
1
.4
)
£
3
.2
(0
.0
6
0
)
£
3
.3
(0
.0
7
2
)
£
0
.1
(2
£
0
.0
5
,
£
0
.3
2
)
£
2
.6
(£
2
.2
,
£
3
)
£
1
2
.8
(£
1
2
.2
,
£
1
3
.3
)
1
.8
1
(1
.6
5
,
1
.9
7
)
4
.8
8
(4
.5
0
,
5
.2
6
)
T
o
ta
l
P
re
sc
ri
p
ti
o
n
co
st
s
£
1
3
7
(1
.7
4
3
)
£
4
3
2
(3
.6
1
4
)
£
2
9
5
(£
2
8
7
,
£
3
0
2
)
£
1
0
6
(0
.5
1
3
)
£
1
4
2
(0
.7
5
3
)
£
3
6
(£
3
4
.3
,
£
3
7
.8
)
£
3
0
.7
(£
2
7
.4
,
£
3
4
.0
3
)
£
2
8
9
(£
2
8
4
,
£
2
9
4
)
1
.2
9
(1
.2
6
,
1
.3
3
)
3
.0
4
(2
.9
8
,
3
.1
0
)
1
St
an
d
ar
d
e
rr
o
r
in
p
ar
e
n
th
e
se
s.
2
co
n
fi
d
e
n
ce
in
te
rv
al
in
p
ar
e
n
th
e
se
s.
3
G
lu
te
n
-f
re
e
an
d
sp
e
ci
al
d
ie
t
p
ro
d
u
ct
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
4
1
3
0
8
.t
0
0
3
Cost of Coeliac Disease before and after Diagnosis
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e41308
T
a
b
le
4
.
A
ve
ra
g
e
an
n
u
al
co
st
s
p
e
r
p
at
ie
n
t
in
C
D
ve
rs
u
s
n
o
n
-C
D
co
h
o
rt
s
st
ra
ti
fi
e
d
b
y
d
at
e
o
f
d
ia
g
n
o
si
s/
p
se
u
d
o
-d
ia
g
n
o
si
s
d
at
e
(1
9
8
7
–
1
9
9
9
;
2
0
0
0
–
2
0
0
5
).
C
a
se
s
C
o
n
tr
o
ls
C
a
se
-C
o
n
tr
o
l
D
if
fe
re
n
ce
C
a
se
s
a
s
a
p
ro
p
o
rt
io
n
o
f
co
n
tr
o
ls
B
e
fo
re
1
(B
)
A
ft
e
r1
(A
)
A
–
B
2
B
e
fo
re
1
(B
)
A
ft
e
r1
(A
)
A
–
B
2
B
e
fo
re
2
A
ft
e
r2
B
e
fo
re
2
A
ft
e
r2
D
ia
g
n
o
si
s/
p
se
u
d
o
-d
ia
g
n
o
si
s
d
at
e
:
1
9
8
7
–1
9
9
9
C
o
n
su
lt
a
ti
o
n
s
co
st
s
£
1
5
8
(2
.5
0
1
)
£
1
7
4
(1
.8
8
4
)
£
1
6
(£
9
.1
,
£
2
1
.6
)
£
1
1
2
(0
.6
0
8
)
£
1
2
8
(0
.5
0
1
)
£
1
6
(£
1
4
.3
,
£
1
7
.5
)
£
4
6
(£
4
2
.3
,
£
5
0
.4
)
£
4
6
(£
4
2
.7
,
£
4
9
.1
)
1
.4
1
(1
.3
7
,
1
.4
6
)
1
.3
6
(1
.3
3
,
1
.3
9
)
T
e
st
s
co
st
s
£
5
.5
(0
.1
8
2
)
£
9
.4
(0
.1
9
3
)
£
3
.9
(£
3
.3
,
£
4
.4
)
£
3
.1
(0
.0
3
9
)
£
7
(0
.0
5
4
)
£
3
.9
(£
3
.7
,
£
4
.1
)
£
2
.4
(£
2
.1
,
£
2
.7
)
£
2
.4
(£
2
,
£
2
.7
)
1
.7
7
(1
.6
6
,
1
.9
0
)
1
.3
4
(1
.2
8
,
1
.4
0
)
O
u
tp
a
ti
e
n
t
re
fe
rr
a
ls
co
st
s
£
4
4
.1
(1
.2
4
7
)
£
2
4
.6
(0
.7
4
6
)
2
£
1
9
.5
(2
£
2
2
.2
,
2
£
1
6
.8
)
£
2
8
.6
(0
.3
6
1
)
£
2
3
.8
(0
.2
6
0
)
2
£
4
.8
(2
£
5
.7
,
2
£
3
.9
)
£
1
5
.5
(£
1
3
.3
,
£
1
7
.7
)
£
0
.8
(2
£
0
.6
4
,
£
2
.3
3
)
1
.5
4
(1
.4
5
,
1
.6
4
)
1
.0
3
(0
.9
7
,
1
.1
0
)
P
re
sc
ri
p
ti
o
n
s
co
st
s
£
1
2
6
(2
.8
9
6
)
£
4
1
9
(4
.4
5
7
)
£
2
9
3
(£
2
8
0
,
£
3
0
6
)
£
9
3
.6
(0
.8
4
6
)
£
1
2
9
(0
.8
8
7
)
£
3
5
.4
(£
3
3
.2
,
£
3
8
.5
)
£
3
2
.4
(£
2
7
.3
,
£
3
8
.3
)
£
2
9
0
(£
2
8
4
,
£
2
9
6
)
1
.3
5
(1
.2
9
,
1
.4
2
)
3
.2
5
(3
.1
7
,
3
.3
3
)
T
o
ta
l
co
st
s
£
3
2
7
(5
.1
4
)
£
6
2
2
(5
.6
4
)
£
2
9
5
(£
2
7
8
,
£
3
1
2
)
£
2
2
8
(1
.3
4
)
£
2
8
0
(5
.1
4
)
£
5
2
(£
4
8
,
£
5
6
)
£
9
9
(£
9
0
.6
,
£
1
0
8
)
£
3
4
2
(£
3
3
4
,
£
3
5
1
)
1
.4
3
(1
.3
9
,
1
.4
8
)
2
.2
2
(2
.1
4
,
2
.3
1
)
D
ia
g
n
o
si
s/
p
se
u
d
o
-d
ia
g
n
o
si
s
d
at
e
:
2
0
0
0
–2
0
0
5
C
o
n
su
lt
a
ti
o
n
s
co
st
s
£
1
6
6
(1
.6
2
4
)
£
2
0
1
(2
.7
1
5
)
£
3
5
(£
2
8
.6
,
£
4
0
.3
)
£
1
2
4
(0
.4
1
9
)
£
1
3
4
(0
.6
5
3
)
£
1
0
(£
8
.7
,
£
1
1
.6
)
£
4
2
(£
3
9
.7
,
£
4
5
.2
)
£
6
7
(£
6
2
.5
,
£
7
1
)
1
.3
4
(1
.3
1
,
1
.3
7
)
1
.5
(1
.4
5
,
1
.5
4
)
T
e
st
s
co
st
s
£
1
0
.4
(0
.1
7
4
)
£
1
8
.9
(0
.4
1
5
)
£
8
.5
(£
7
.7
,
£
9
.2
)
£
6
.2
(0
.0
4
2
)
£
1
1
.5
(0
.0
8
6
)
£
5
.3
(£
5
.2
,
£
5
.5
)
£
4
.2
(£
4
,
£
4
.5
)
£
7
.4
(£
6
.8
,
£
7
.9
)
1
.6
8
(1
.6
2
,
1
.7
4
)
1
.6
4
(1
.5
6
,
1
.7
1
)
O
u
tp
a
ti
e
n
t
re
fe
rr
a
ls
co
st
s
£
3
7
(0
.8
0
5
)
£
3
1
.4
(1
.1
1
2
)
2
£
5
.6
(2
£
8
.3
3
,
2
£
2
.8
5
)
£
2
5
(0
.2
2
1
)
£
2
3
.9
(0
.3
3
5
)
2
£
1
.1
(2
£
1
.8
,
2
£
0
.2
3
)
£
1
2
(£
1
0
.7
,
£
1
3
.4
)
£
7
.5
(£
5
.5
,
£
9
.5
)
1
.4
8
(1
.4
1
,
1
.5
5
)
1
.3
1
(1
.2
2
,
1
.4
1
)
P
re
sc
ri
p
ti
o
n
s
co
st
s
£
1
4
1
(2
.1
4
3
)
£
4
5
0
(6
.0
7
)
£
3
0
9
(£
2
9
9
,
£
3
1
9
)
£
1
1
1
(0
.6
3
3
)
£
1
6
2
(1
.3
3
3
)
£
5
1
(£
4
8
.1
,
£
5
3
.2
)
£
3
0
(£
2
5
.7
,
£
3
3
.9
)
£
2
8
8
(£
2
7
9
,
£
2
9
7
)
1
.2
7
(1
.2
3
,
1
.3
1
)
2
.7
8
(2
.6
9
,
2
.8
6
)
T
o
ta
l
co
st
s
£
3
4
5
(3
.5
9
)
£
6
9
2
(8
.0
6
)
£
3
4
7
(£
3
3
1
,
£
3
6
1
)
£
2
5
7
(0
.9
7
)
£
3
2
1
(1
.8
4
)
£
6
4
(£
6
0
.5
,
£
6
8
)
£
8
8
(£
8
1
.8
,
£
9
4
.6
)
£
3
7
1
(£
3
5
8
,
£
3
8
2
)
1
.3
4
(1
.3
1
,
1
.3
7
)
2
.1
6
(2
.1
0
,
2
.2
1
)
1
St
an
d
ar
d
e
rr
o
r
in
p
ar
e
n
th
e
se
s.
2
C
o
n
fi
d
e
n
ce
in
te
rv
al
in
p
ar
e
n
th
e
se
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
4
1
3
0
8
.t
0
0
4
Cost of Coeliac Disease before and after Diagnosis
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e41308
patients may undergo screening for comorbid conditions, such as
vitamin and mineral deficiencies, anaemia and osteoporosis. Such
activity, however, reduces sharply during the subsequent years and
in our data stabilised about six years after diagnosis, but at a level
much higher than the pre-diagnosis average cost. Analyses of
average per-patient annual healthcare costs stratified by age group
at diagnosis also showed that diagnosis in older individuals (46 or
more) resulted in higher costs than diagnosis in young (0–18) and
younger adults (19–45). Diagnosis earlier in the life of an
individual, therefore, may help reduce healthcare costs.
This first result seems, at first glance, in clear contrast with the
sparse previously published empirical evidence. Previous studies
[19,20] found that direct medical total costs reduced significantly
for CD patients after diagnosis. Those investigations, however,
were carried out in the US, which has a very different healthcare
system from the UK NHS, and in particular where costs of
pharmaceutical prescriptions were not covered. In the UK,
prescription medicines are mainly prescribed by NHS doctors
and are typically taken to a pharmacy to be dispensed. In England,
a prescription fee of £7.40 per item is charged (as of 1 April 2011)
[41], although the elderly, those on low incomes and patients with
chronic diseases are exempt; prescription charges have been
completely abolished in Wales [42], Scotland [43] and Northern
Ireland [44]. Consequently, the US finding of a reduction in
medical costs following CD diagnosis and treatment may hide a
shift of the economic costs to patients, as the additional costs of
adhering to a gluten-free diet are not reimbursed to the patients, in
contrast to the UK, where individuals diagnosed with CD are
prescribed gluten-free products. The results of our study corrob-
orate this hypothesis.
Similarly to the US results, coeliac patients in our study
underwent a post-diagnosis reduction in referral costs. This
partially counterbalanced the slightly higher level of costs for
consultations and tests (but not prescriptions) in the post-diagnosis
period. Increased consultations and tests may occur because CD
patients have to be checked at regular intervals by a healthcare
team, including a GP and a dietician, in order to monitor
adherence to a gluten-free diet and to reinforce the importance of
such compliance [38]. Additionally, higher rates of consultations
and tests may be due to comorbidities associated with CD.
Differently from the US studies, our analyses included costs of
prescriptions, which were found to be the major driver of the
increase in post-diagnosis CD costs. Noticeably, prescriptions costs
for BNF category 9 ‘Nutrition and blood’, which includes gluten-
free products, underwent a 25-fold increase from an average
annual pre-diagnosis cost of £10 to an average of £246 post-
diagnosis per coeliac patient, 89% of the latter cost represented by
prescriptions for food supplements (gluten-free and special diet
products).
Increased post-diagnosis prescription costs for CD patients were
also identified in other BNF categories (e.g. gastrointestinal,
respiratory, nervous systems, endocrinology etc). This may
represent further evidence on the cumulative morbidity experi-
enced by CD patients compared with the general population [39].
A variety of health problems mainly due to untreated disease, and
which can persist in the absence of compliance with a gluten-free
diet, has been discussed in previous studies [10,39].
The stratification of healthcare costs by calendar year of
diagnosis indicated that, on average, cases cost 43% more than
controls before diagnosis up to 1999, compared with 34% more in
Figure 2. Total costs before and after diagnosis (or pseudo-diagnosis) of coeliac disease.
doi:10.1371/journal.pone.0041308.g002
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the post-1999 period. After diagnosis, the difference remained
almost unchanged. This is compatible with the hypothesis that
improved methods for detecting CD – notably wide adoption of
serological testing – and a higher awareness of the disease and its
symptoms among health professionals [2], led to a reduction in the
number of consultations and tests performed prior to diagnosis.
In evaluating the healthcare costs attributable to CD prior to
diagnosis, we found that the average cost per patient with
undetected and untreated CD was 37% higher than the
corresponding cost for a patient in the control-cohort. Cost
comparisons between cases and controls up to 10 years after
diagnosis showed that diagnosis and treatment of CD did not
reduce direct healthcare cost in aggregate, but did reduce costs of
tests (by 21%) and referrals (by 37%).
Our estimates of the costs of undiagnosed and diagnosed CD
will help inform clinical and public health policy, facilitate the
economic evaluation of diagnostic and treatment interventions,
complement the existing NICE guidelines on the management of
CD [7], and may increase policymakers’ awareness of the potential
costs savings deriving from early identification of CD.
Other strengths of this study include the large sample size, the
time frame of 20 years, which was considerably longer than those
adopted in previous published studies [19,20], the wide geograph-
ical coverage of the study population, the accuracy and reliability
of the GPRD dataset in a primary care setting and the richness of
clinical details included in it. These features allowed us to obtain
an accurate classification of the patients included in our study, and
to produce results that we believe are broadly generalisable to the
whole population of the UK. The use of the GPRD posed many
challenges to our analyses, notably difficulties in processing such a
large and extremely complex dataset, and making full use of all the
relevant clinical and pharmaceutical products codes. Only a small
number of studies have previously used the GPRD for studying
CD, mainly from an epidemiological perspective [23,45]. Our use
of the database to evaluate the economic implications of CD
diagnosis emerges, therefore, as novel.
Several limitations of our study should be noted. Firstly, we used
a fixed unit cost for each resource category during the whole 20-
year period of our analyses. Although this is a standard practice in
cost studies and was dictated by the lack of a long time series of
unit costs, it might result in our total costs being slightly
overestimated. Secondly, although cases and controls were
identified on a ratio of 1:10 and matched by age, sex and practice,
we did not match by registration year. We also discarded single
individuals if they had missing values in some of the relevant
variables. Analyses were therefore conducted on a variable
number of cases and controls over the duration of the study and
did not strictly follow a matched case-control design. However, we
consider it unlikely that this will have had a significant impact on
our results, given the sample sizes involved. Thirdly, whilst GPRD
is an accurate source of resource use data in the primary care
context, the capture of data for secondary care resource use is, by
the intrinsic nature of the dataset, less precise, especially with
respect to inpatient episodes and follow-up outpatient visits. We
have consequently not attempted to include these, and only
include initial outpatient referrals from the GP to secondary care.
Figure 3. Total costs before and after diagnosis (or pseudo-diagnosis) of coeliac disease. Comparison between PRE-2000 and POST-1999
DIAGNOSIS.
doi:10.1371/journal.pone.0041308.g003
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GPRD now permits linkage of patient records to the Hospital
Episodes Statistics database, and this will permit future research to
more fully capture the primary-secondary care interface and
reliably quantify hospital use in the coeliac and non-coeliac
population. Fourthly, we focused only on the evaluation of direct
costs incurred or initiated by NHS primary care services and did
not include indirect costs associated with reduced productivity
caused by impaired ability to work and absence from work, out-of-
pocket costs such as those incurred in following a special and
expensive diet, and other costs to those with coeliac disease and
their families.
In addition to economic costs, CD also imposes a significant
impact on quality of life [34,46,47,48,49,50,51,52,53]. Some
studies have shown that the symptoms of undiagnosed CD are
associated with a prolonged and substantial decrement of quality
of life [34], while long-term dietary compliance generally improves
quality of life [50,52]. However, other studies have suggested that,
even after years of compliance with a gluten-free diet, many
patients with CD consider it a significant inconvenience
[46,47,48,49,51,53]. Our results need to be interpreted in light
of these findings: new strategies to diagnose and treat CD will
impact not only on direct healthcare costs, but also the quality of
life of patients.
In conclusion, this study provides a uniquely detailed descrip-
tion of healthcare costs before and after diagnosis of CD in the UK
healthcare system. By identifying and quantifying the relative
contribution of different types of resource use to the primary care
costs of each CD patient, and comparing these to carefully
matched controls, this study may provide insights into the
potential cost impact and cost-effectiveness of new ways of
detecting and treating CD.
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